ClinicalTrials.gov record
Completed Phase 2 Interventional

A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide

ClinicalTrials.gov ID: NCT04669665

Public ClinicalTrials.gov record NCT04669665. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 10:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 2-part Phase 2 Study to Assess the Efficacy, Safety, and Tolerability of SLS-002 (Intranasal Racemic Ketamine) Administered to Adults With Major Depressive Disorder at Imminent Risk of Suicide

Study identification

NCT ID
NCT04669665
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Seelos Therapeutics, Inc.
Industry
Enrollment
164 participants

Conditions and interventions

Interventions

  • Intranasal device Device
  • Placebo Drug
  • SLS-002 Drug
  • Standard of care Other

Device · Drug · Other

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 16, 2020
Primary completion
Jun 16, 2023
Completion
Jul 13, 2023
Last update posted
Sep 27, 2023

2020 – 2023

United States locations

U.S. sites
21
U.S. states
11
U.S. cities
21
Facility City State ZIP Site status
Seelos Investigational Site Orange California 92868
Seelos Investigational Site Panorama City California 91402
Seelos Investigational Site San Diego California 92103
Seelos Investigational Site Hollywood Florida 33021
Seelos Investigational Site Miami Florida 33144
Seelos Investigational Site Miami Lakes Florida 33016
Seelos Investigational Site Miramar Florida 33025
Seelos Investigational Site Oakland Park Florida 33324
Seelos Investigational Site Atlanta Georgia 30331
Seelos Investigational Site Decatur Georgia 30030
Seelos Investigational Site Springfield Illinois 62781
Seelos Investigational Site Gaithersburg Maryland 20877
Seelos Investigational Site Flowood Mississippi 39232
Seelos Investigational Site Buffalo New York 14215
Seelos Investigational Site Cincinnati Ohio 45219
Seelos Investigational Site North Canton Ohio 44720
Seelos Investigational Site DeSoto Texas 75115
Seelos Investigational Site Houston Texas 77054
Seelos Investigational Site Richardson Texas 75080
Seelos Investigational Site Salt Lake City Utah 84108
Seelos Investigational Site Morgantown West Virginia 26505

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04669665, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 27, 2023 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04669665 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →